These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31431499)

  • 1. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.
    Anderson C; Nichols HB; House M; Sandler DP
    Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
    Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
    J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-benefit profiles of women using tamoxifen for chemoprevention.
    Nichols HB; DeRoo LA; Scharf DR; Sandler DP
    J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer prevention trials.
    Rhodes DJ; Hartmann LC; Perez EA
    Curr Oncol Rep; 2000 Nov; 2(6):558-65. PubMed ID: 11122893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.
    Pinsky PF; Miller E; Heckman-Stoddard B; Minasian L
    Am J Obstet Gynecol; 2018 Jun; 218(6):606.e1-606.e9. PubMed ID: 29630889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
    Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
    J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    Levine M; Moutquin JM; Walton R; Feightner J;
    CMAJ; 2001 Jun; 164(12):1681-90. PubMed ID: 11450210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
    Waters EA; McNeel TS; Stevens WM; Freedman AN
    Breast Cancer Res Treat; 2012 Jul; 134(2):875-80. PubMed ID: 22622807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast Cancer Chemoprevention in an Integrated Health Care Setting.
    Nichols HB; Stürmer T; Lee VS; Anderson C; Lee JS; Roh JM; Visvanathan K; Muss H; Kushi LH
    JCO Clin Cancer Inform; 2017 Nov; 1():1-12. PubMed ID: 30657366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention of breast cancer.
    Brown PH; Lippman SM
    Breast Cancer Res Treat; 2000 Jul; 62(1):1-17. PubMed ID: 10989982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).
    Holmberg C; Waters EA; Whitehouse K; Daly M; McCaskill-Stevens W
    Med Decis Making; 2015 Nov; 35(8):1010-22. PubMed ID: 26183166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
    Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
    Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
    Vogel VG
    Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of tamoxifen and raloxifene for the prevention of breast cancer.
    Wickerham DL; Costantino JP; Vogel VG; Cronin WM; Cecchini RS; Ford LG; Wolmark N
    Recent Results Cancer Res; 2009; 181():113-9. PubMed ID: 19213563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current concepts in breast cancer chemoprevention.
    Chlebowski RT
    Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of breast cancer.
    Thomsen A; Kolesar JM
    Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.